ATOS Historical PE Ratio Notes

— Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company focused primarily on developing innovative therapies for breast cancer and other breast conditions. The company's pipeline includes proprietary, targeted treatments aiming to address unmet needs in oncology, particularly hormonal and localized therapies for breast cancer prevention & treatment. When examining ATOS's historical PE ratio, it's crucial to note that as a clinical-stage company, Atossa typically reports little or no recurring revenue and negative earnings, since its assets are primarily in research & development phases rather than generating commercial sales. Consequently, historical PE ratios for ATOS are often either extremely high, not meaningful, or simply unreported (shown as ȁcN/Aȁd or ȁc--ȁd in many financial filings and charting tools). This reflects limited or negative earnings rather than investor consensus on valuation. Traditional PE analysis is less applicable here, so when you review historical price, earnings, and PE ratio charts for ATOS, focus more on major company milestones—such as clinical trial results, regulatory progress, and financing events—which tend to drive price changes far more than underlying earnings.

On this page we presented the Atossa Therapeutics Historical PE Ratio information for Atossa Therapeutics' stock. The average ATOS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 18.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ATOS historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ATOS historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for ATOS had been 4.85, and the most recent quarterly earnings result, annualized, was 16.8. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent ATOS PE on 5/15/2026 based on annualized quarterly EPS was 0.3. Based on ATOS's history, that recent PE is low relative to the historical average, with the recent PE 98.3% lower than the historical average PE across our data set for Atossa Therapeutics.

For self directed investors doing their due diligence on ATOS or any other given stock, valuation analysis for ATOS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Atossa Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ATOS. Thanks for visiting, and the next time you need to research ATOS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.